As closed-door talks for the Trans-Pacific Partnership Agreement resume in Singapore this week, international medical humanitarian organization Médecins Sans Frontières calls on the US government to end its stall tactics and revise its proposals for what otherwise promises to be the most harmful trade deal ever for access to medicines in developing countries.
Days before leaders of the European Union arrived in Norway to collect this year’s Nobel Peace prize, Thai public health activists sent a letter to the northern powerhouse, warning that the EU’s 2012 accolades face a credibility test in this Southeast Asian country.
As free trade talks with the European Union reach the endgame, Ottawa is signalling it is prepared to give the Europeans at least part of what they asked for on drug patents — a move that could cost Canadians up to $900 million a year.
A concession on drug patents in a free trade deal with the European Union stands to cost Nova Scotians millions, Health and Wellness Minister David Wilson said Wednesday.
Civil society statement calling fpr rejection of the Conformity Assessment and Acceptance of Industrial Products protocol attached to the European Union-Israel Association Agreement
Although the EU is asking Canada to change its patent regime, it is not possible to do so just for the EU. The actual beneficiaries would be all of the world’s brand-name companies. Of the world’s top 12 health care companies by revenue only three or four are resident in the EU.
People afflicted with the Aids virus have called on the government to proceed carefully on free-trade negotiations with the European Union, as the latter’s demands for copyright protection could make it difficult for patients to access cheap medicines.
Some countries whose governments purchase drugs with a set budget are also alarmed by signs that the TPP may grant new negotiating powers to the industry.
India has asked Japan to remove all non-tax barriers to help the domestic industry take advantage of the comprehensive free-trade agreement and increase share in the Japanese market.
The letter warns that the TRIPS-Plus provisions in the trade agreement between EU and Thailand – including border measures, data exclusivity, patent term extensions, and protection for new indications – would block access to generic medicines.
Just Foreign Policy is offering a reward, now up to $21,100, to WikiLeaks if it publishes a draft copy of the TPP. People could add to the reward fund, or if in a position to do so, make a copy of the draft agreement available to the world.
Malaysian Health Minister Datuk Seri Liow Tiong Lai said the Trans-Pacific Partnership Agreement, which is being negotiated among eleven countries including the US and Malaysia, would be detrimental to the local medical industry.
As the nineteenth International AIDS Conference continued in Washington Tuesday, thousands of protesters marched on the White House calling for an end to free trade deals that protesters argue make vital AIDS medicines unaffordable.
Delayed market entry of generics due to enhanced intellectual property protection cost Jordanian private consumers approximately 18 million US dollars annually
Former Canadian Prime Minister Brian Mulroney is wading into the high-stakes debate over patent protection in the free trade talks with Europe, and he’s clearly taking sides.
The provincial premiers have undertaken a letter-writing campaign to demand compensation from the federal government for any increase in drug costs that might results from a free-trade agreement with Europe.
There’s a debate raging over Canada’s intellectual property regime. If one side’s right, Canada stands to pay $2.8 billion more every year in drug costs while it undermines its generic-drug manufacturing sector.
As the South Korea-United States Free Trade Agreement (KORUS FTA) takes effects Thursday, some are expecting new trade pressures from the US, including moves to open the beef market. In particular, South Korea will be forced to sit down at the negotiating table if the US requests negotiations on beef.
With just days left before the implementation of the US-Korea free trade agreement Washington is drawing attention to a little publicized area of the trade treaty, the part covering the pricing of medicine in Korea. The US says it wants more transparency; the Korean pharmaceutical industry says it wants to maintain control over pricing domestically.
Negotiations of the Transpacific Partnership Agreement (TPP) have turned to discussions of the pharmaceutical reimbursement chapter. This issue is highly controversial and represents a very recent shift in US trade policy.